Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2014 Financial Results and Provides Update on 2015 Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. MU
8. DFTX
9. HOOD
10. RGNX

Go back to Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2014 Financial Results and Provides Update on 2015 Outlook

Emergent BioSolutions (EBS) Tops Q1 EPS by 6c, Comments on Ongoing Internal Manufacturing Investigation

March 5, 2015 4:16 PM EST

Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.75, $0.06 better than the analyst estimate of $0.69. Revenue for the quarter came in at $148 million versus the consensus estimate of $147 million.

Ongoing Internal Manufacturing Investigation

Beginning on January 28, 2015, during standard quality inspections performed in accordance with customary procedures, the company discovered foreign particles in a limited number of vials in two manufactured lots of BioThrax. In order... More